CEimpact Podcast

HIV treatment has evolved significantly, offering streamlined regimens and improved patient outcomes. This episode will discuss the latest antiretroviral therapy (ART) guidelines, highlighting preferred regimens, key pharmacologic considerations, and practical counseling strategies for pharmacists. Tune in to enhance your clinical knowledge and play a pivotal role in optimizing care for individuals living with HIV.  Joshua Davis Kinsey, PharmD VP, Education CEimpact Rachel Maynard, PharmD Lead Editor Pyrls Joshua Davis Kinsey and Rachel Maynard have no relevant financial relationships to disclose.  BONUS: With this episode, you also get exclusive, FREE access to beautifully designed clinical charts and practice resources from our friends at Pyrls, that you can use in your everyday practice. Click the links below to access these practical tools: * HIV Pharmacotherapy [https://ceimpactfilestorage.blob.core.windows.net/$web/Partners/Pyrls_HIV_Pharmacotherapy.pdf] * HIV Medications [https://ceimpactfilestorage.blob.core.windows.net/$web/Partners/Pyrls_HIV_Medications.pdf] * And more! [https://www.pyrls.com/ceimpact-pyrls]   Pharmacist Members, REDEEM YOUR CPE HERE [https://learn.ceimpact.com/course-landing/8783]!   Not a member? Get a Pharmacist Membership [https://www.ceimpact.com/pharmacist_membership/] & earn CE for GameChangers Podcast episodes! (30 mins/episode) CPE INFORMATION Learning Objectives Upon successful completion of this knowledge-based activity, participants should be able to: 1. Identify current guideline-recommended antiretroviral therapy (ART) regimens and their key components. 2. Describe important counseling points for pharmacists supporting patients on HIV treatment, including adherence, side effects, and drug interactions. 0.05 CEU/0.5 Hr UAN: 0107-0000-25-245-H02-P Initial release date: 7/21/2025 Expiration date: 7/21/2026 Additional CPE details can be found here [https://learn.ceimpact.com/library/course/8783]. Follow CEimpact on Social Media: LinkedIn [https://www.linkedin.com/company/ceimpact] Instagram [https://www.instagram.com/ceimpactrx/]

Integrative oncology blends conventional cancer treatments with supportive therapies like nutrition, acupuncture, and mind-body practices to improve patient outcomes and quality of life. This episode outlines what pharmacists need to know about the principles of integrative medicine, how to evaluate evidence-based resources, and counseling tips for guiding patients through safe, effective complementary options. Tune in to strengthen your ability to support cancer patients with credible, compassionate, and comprehensive care.  HOST Joshua Davis Kinsey, PharmD VP, Education CEimpact GUEST Ginger Blackmon, PharmD Associate Director of Clinical Initiatives  NCODA Joshua Davis Kinsey and Ginger Blackmon have no relevant financial relationships to disclose. Pharmacist Members, REDEEM YOUR CPE HERE [https://learn.ceimpact.com/course-landing/8780]!   Not a member? Get a Pharmacist Membership [https://www.ceimpact.com/pharmacist_membership/] & earn CE for GameChangers Podcast episodes! (30 mins/episode) CPE INFORMATION Learning Objectives Upon successful completion of this knowledge-based activity, participants should be able to: 1. Define integrative oncology and identify its role in supporting patients undergoing conventional cancer treatment. 2. Describe how pharmacists can evaluate and counsel on evidence-based complementary therapies used in integrative oncology. 0.05 CEU/0.5 Hr UAN: 0107-0000-25-257-H01-P Initial release date: 7/14/2025 Expiration date: 7/14/2026 Additional CPE details can be found here [https://learn.ceimpact.com/library/course/8780]. Follow CEimpact on Social Media: LinkedIn [https://www.linkedin.com/company/ceimpact] Instagram [https://www.instagram.com/ceimpactrx/]

Integrative oncology blends conventional cancer treatments with supportive therapies like nutrition, acupuncture, and mind-body practices to improve patient outcomes and quality of life. This episode outlines what pharmacists need to know about the principles of integrative medicine, how to evaluate evidence-based resources, and counseling tips for guiding patients through safe, effective complementary options. Tune in to strengthen your ability to support cancer patients with credible, compassionate, and comprehensive care. HOST Joshua Davis Kinsey, PharmD VP, Education CEimpact GUEST Ginger Blackmon,PharmD Associate Director of Clinical Initiatives  NCODA Joshua Davis Kinsey and Ginger Blackmon have no relevant financial relationships to disclose.   Pharmacist Members, REDEEM YOUR CPE HERE [https://learn.ceimpact.com/course-landing/8645]!   Not a member? Get a Pharmacist Membership [https://www.ceimpact.com/pharmacist_membership/] & earn CE for GameChangers Podcast episodes! (30 mins/episode) CPE INFORMATION Learning Objectives Upon successful completion of this knowledge-based activity, participants should be able to: 1. Define integrative oncology and identify its role in supporting patients undergoing conventional cancer treatment. 2. Describe how pharmacists can evaluate and counsel on evidence-based complementary therapies used in integrative oncology. 0.05 CEU/0.5 Hr UAN: 0107-0000-25-256-H01-P Initial release date: 7/7/2025 Expiration date: 7/7/2028 Additional CPE details can be found here [https://learn.ceimpact.com/library/course/8645]. Follow CEimpact on Social Media: LinkedIn [https://www.linkedin.com/company/ceimpact] Instagram [https://www.instagram.com/ceimpactrx/]

Dyslipidemia remains a major contributor to cardiovascular disease, and pharmacists play a key role in optimizing therapy and improving outcomes. This episode reviews recent updates in guidelines, pharmacologic options, and practical counseling tips for supporting patients with lipid disorders. Tune in to strengthen your clinical impact and support long-term health for the patients you serve. HOST Joshua Davis Kinsey, PharmD VP, Education CEimpact GUEST Janelle Ruisinger, PharmD, FAPhA Clinical Professor The University of Kansas School of Pharmacy Pharmacist Members, REDEEM YOUR CPE HERE [https://learn.ceimpact.com/course-landing/8561]!   Not a member? Get a Pharmacist Membership [https://www.ceimpact.com/pharmacist_membership/] & earn CE for GameChangers Podcast episodes! (30 mins/episode) CPE INFORMATION Learning Objectives Upon successful completion of this knowledge-based activity, participants should be able to: 1. Describe current guidelines and evidence-based pharmacologic options for managing dyslipidemia. 2. Identify key counseling strategies pharmacists can use to support adherence and improve lipid-related outcomes. 0.05 CEU/0.5 Hr UAN: 0107-0000-25-226-H01-P Initial release date: 6/30/2025 Expiration date: 6/30/2026 Additional CPE details can be found here [https://learn.ceimpact.com/library/course/8561]. Follow CEimpact on Social Media: LinkedIn [https://www.linkedin.com/company/ceimpact] Instagram [https://www.instagram.com/ceimpactrx/]

Fatty liver disease affects a growing number of patients, often progressing silently until advanced stages. This episode highlights what pharmacists need to know about recent terminology changes, risk factors, pharmacotherapy updates, and key counseling strategies to support patients. Tune in to sharpen your clinical knowledge and help identify, manage, and educate patients at risk for this increasingly common condition. HOST Joshua Davis Kinsey, PharmD VP, Education CEimpact GUEST Sarah Wheeler, PharmD, BCACP, CDCES Assistant Professor VCU School of Pharmacy Pharmacist Members, REDEEM YOUR CPE HERE [https://learn.ceimpact.com/course-landing/8525]!   Not a member? Get a Pharmacist Membership [https://www.ceimpact.com/pharmacist_membership/] & earn CE for GameChangers Podcast episodes! (30 mins/episode) CPE INFORMATION Learning Objectives Upon successful completion of this knowledge-based activity, participants should be able to: 1. Describe current terminology, risk factors, and stages associated with fatty liver disease. 2. Identify evidence-based pharmacologic and non-pharmacologic strategies that pharmacists can use to support patients with or at risk for fatty liver disease. 0.05 CEU/0.5 Hr UAN: 0107-0000-25-219-H01-P Initial release date: 6/23/2025 Expiration date: 6/23/2026 Additional CPE details can be found here [https://learn.ceimpact.com/library/course/8525]. Follow CEimpact on Social Media: LinkedIn [https://www.linkedin.com/company/ceimpact] Instagram [https://www.instagram.com/ceimpactrx/]